Literature DB >> 6682967

Hypoglycemia, hepatic dysfunction, muscle weakness, cardiomyopathy, free carnitine deficiency and long-chain acylcarnitine excess responsive to medium chain triglyceride diet.

A M Glasgow, A G Engel, D M Bier, L W Perry, M Dickie, J Todaro, B I Brown, M F Utter.   

Abstract

Fraternal twins who had fasting hypoglycemia, hypoketonemia, muscle weakness, and hepatic dysfunction are reported. The hepatic dysfunction occurred only during periods of caloric deprivation. The surviving patient developed a cardiomyopathy. In this sibling, muscle weakness and cardiomyopathy were markedly improved by a diet high in medium chain triglycerides. There was a marked deficiency of muscle total carnitine and a mild deficiency of hepatic total carnitine. Unlike patients with systemic carnitine deficiency, serum and muscle long-chain acylcarnitine were elevated and renal reabsorption of carnitine was normal. It was postulated that the defect in long-chain fatty acid oxidation in this disorder is caused by an abnormality in the mitochondrial acylcarnitine transport. Detailed studies of the cause of the hypoglycemia revealed that insulin, growth hormone, cortisol, and glucagon secretion were appropriate and that it is unlikely that there was a major deficiency of a glycolytic or gluconeogenic enzyme. Glucose production and alanine conversion to glucose were in the low normal range when compared to normal children in the postabsorptive state. The hypoglycemia in our patients was probably due to a modest increase in glucose consumption, secondary to the decreased oxidation of fatty acids and ketones, alternate fuels which spare glucose utilization, plus a modest decrease in hepatic glucose production secondary to decreased available hepatic energy substrates.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6682967     DOI: 10.1203/00006450-198305000-00003

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  16 in total

1.  A carnitine/acylcarnitine translocase assay applicable to biopsied muscle specimens without requiring mitochondrial isolation.

Authors:  M S Murthy; V S Kamanna; S V Pande
Journal:  Biochem J       Date:  1986-05-15       Impact factor: 3.857

2.  L-3-hydroxyacyl-CoA dehydrogenase deficiency: two cases with pigmentary retinopathy.

Authors:  J Uusimaa; L Vainionpää; S Similä; R Miettinen; M Nuutinen
Journal:  J Inherit Metab Dis       Date:  1997-11       Impact factor: 4.982

Review 3.  Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency.

Authors:  Robert Ringseis; Janine Keller; Klaus Eder
Journal:  Eur J Nutr       Date:  2011-12-02       Impact factor: 5.614

Review 4.  Disorders of mitochondrial fatty acyl-CoA beta-oxidation.

Authors:  R J Wanders; P Vreken; M E den Boer; F A Wijburg; A H van Gennip; L IJlst
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

5.  3-Hydroxydicarboxylic aciduria due to long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency associated with sudden neonatal death: protective effect of medium-chain triglyceride treatment.

Authors:  M Duran; R J Wanders; J P de Jager; L Dorland; L Bruinvis; D Ketting; L Ijlst; F J van Sprang
Journal:  Eur J Pediatr       Date:  1991-01       Impact factor: 3.183

6.  Systolic blood pressure in babies of less than 32 weeks gestation in the first year of life. Northern Neonatal Nursing Initiative.

Authors: 
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-01       Impact factor: 5.747

Review 7.  l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism.

Authors:  K L Goa; R N Brogden
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

8.  Acute dilated cardiomyopathy in a patient with deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase.

Authors:  Peter C Dyke; Laura Konczal; Dennis Bartholomew; Kim L McBride; Timothy M Hoffman
Journal:  Pediatr Cardiol       Date:  2008-12-16       Impact factor: 1.655

9.  Combined enzyme defect of mitochondrial fatty acid oxidation.

Authors:  S Jackson; R S Kler; K Bartlett; H Briggs; L A Bindoff; M Pourfarzam; D Gardner-Medwin; D M Turnbull
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

10.  Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency--diagnosis, plasma carnitine fractions and management in a further patient.

Authors:  R Moore; J F Glasgow; M A Bingham; J A Dodge; R J Pollitt; S E Olpin; B Middleton; K Carpenter
Journal:  Eur J Pediatr       Date:  1993-05       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.